Michael is active in matters related to patent prosecution, litigation and diligence in the life sciences and biotechnology arena. Michael has significant experience practicing before the USPTO and in a range of patent litigation matters, including drafting pleadings and discovery. Michael’s areas of technical knowledge include molecular biology, antibodies and antibody-based therapies, vaccines, biologics, nanoparticles, biomarkers, diagnostic methods and genetic testing. Michael has recently helped secure the following patents:

  • U.S. Patent No. (Not Yet Assigned) – Nanotechnology Approach for Inhalation Therapies
  • U.S. Patent No. (Not Yet Assigned) – Expression of Triple-Helical Collagen-Like Products in E. coli
  • U.S. Patent No. 9,340,831 – Gel-tethered Molecular Beacons
  • U.S. Patent No. 9,328,368 – Labeled Biomolecular Compositions and Methods for the Production and Uses Thereof
  • U.S. Patent No. 9,314,497 – E2F as a Target of Hormone Refractory Prostate Cancer
  • U.S. Patent No. 9,295,710 – Treatment and Diagnosis of Inflammatory Disorders and HIV
  • U.S. Patent No. 9,260,761 – Assays for Short Sequence Variants
  • U.S. Patent No. 9,238,066 – Proteins Expressed by Mycobacterium tuberculosis and not by BCG and their Use as Diagnostic Reagents and Vaccines
  • U.S. Patent No. 9,125,835 – Synergistic Combinations To Reduce Particle Dose for Targeted Treatment of Cancer and Its Metastases
  • U.S. Patent No. 9,114,092 – Nanotopography-Mediated Reverse Uptake Platform for Nucleic Acid

Michael has a particular interest in the developing field of biologics/biosimilars and the intersection between the scientific, regulatory and patent challenges that the emerging field poses. Possessing an advanced degree in biotechnology with a concentration in bioscience regulatory affairs from Johns Hopkins University, Michael has a concrete understanding of the technology and business concerns that clients seek to protect.

Before Fox Rothschild

Prior to joining the firm, Michael worked in the Intellectual Property Transactions and Rights Management practice at a nationwide law firm. He also has experience serving as a law clerk for a civil litigation boutique in Pittsburgh.

Beyond Fox Rothschild

Michael served as a staff editor for volume 74 and as one of two executive editors for volume 75 of the University of Pittsburgh Law Review, in which he authored the article “Generics and Biosimilars: Mapping the Biosimilars Regulatory Approval Pathway Against the Hatch-Waxman Act and Projecting Futures Effects on the Biologics Market and Patent Protection.”


  • ABA-BNA Award for Excellence in the Study of Intellectual Property Law (2015)
  • Intellectual Property Law Student Leadership Award (2013)
  • CALI Award for Highest Grade in: Trademark Law (2014); Foundations of Intellectual Property (2013); Patent Law Practice (2013); Civil Procedure (2012); and Criminal Procedure (2012)